A groundbreaking advancement in technology has emerged: scientists have developed a bio-computer using human cells. This ...

This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...

The FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with ...

What were the vibes like at BIO 2026? STAT reporters take you inside the annual industry conference on the latest episode of ...

Merck KGaA agreed to buy Bio-Techne Corporation for about $11.3 billion to bolster its life-science business, marking the ...

Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants.    | Orca Bio has jumped into ...

Orca Bio, a commercial-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the U.S. Food and Drug Administration (FDA) has ...

Terrestrial Bio has dosed the first patients in a Phase I clinical trial evaluating its patch that delivers GLP-1 therapeutic ...